Charu Kanwal

Primary Endothelial Damage Is the Mechanism of Cardiotoxicity of Tubulin-Binding Drugs

Igor Mikaelian, Maria-Cristina de Vera-Mudry, Charu Kanwal et al. · Toxicological Sciences · 2010 · 62 citations · Full text

Primary Endothelial Damage, Endothelial Cells, Tubulin-binding Drugs +21

Temporal Gene Expression Profiling Indicates Early Up-regulation of Interleukin-6 in Isoproterenol-induced Myocardial Necrosis in Rat

Igor Mikaelian, Denise Coluccio, Kevin T. Morgan et al. · Toxicologic Pathology · 2008 · 40 citations

Cardiac Muscle, Heart Failure, Early Up-regulation +21

Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy

Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak et al. · Annals of Oncology · 2019 · 30 citations · Full text

Platinum-based Regimens, Metastatic Urothelial Cancer, Urology +7

Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

Windy Berkofsky‐Fessler, Tri Q. Nguyen, Paul Delmar et al. · Molecular Cancer Therapeutics · 2009 · 24 citations

Preclinical Biomarkers, Biomarker (Medicine), Preclinical Drug Evaluation +15

Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.

Daniel P. Petrylak, Scott T. Tagawa, Rohit Jain et al. · Journal of Clinical Oncology · 2020 · 19 citations

Immunology, Immunoediting, Prior Checkpoint Inhibitor +22